GlassScriptPhysician profile
Kayla E Leach-Frasca
NPI 1598113268
$800.76
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $387 · 2024: $413.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $801.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $800.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $181.20 | 2023-2024 | Zepbound, Jardiance, Mounjaro |
| Novo Nordisk INC | $125.95 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $99.63 | 2023-2024 | Prolia, Evenity, Otezla |
| Boston Scientific Corporation | $94.73 | 2023-2024 | Watchman Flx |
| Pfizer INC. | $79.38 | 2023-2024 | |
| Shield Therapeutics INC | $58.14 | 2023-2024 | Accrufer |
| Glaxosmithkline, LLC. | $53.72 | 2023-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Astellas Pharma US INC | $36.26 | 2024 | Veozah |
| Abbvie INC. | $19.04 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $18.74 | 2023 | Camzyos |
| Exact Sciences Corporation | $18.66 | 2023 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $15.31 | 2024 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kayla Leach-Frasca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.